Longevity & AgingDual Aging Therapy Boosts Lifespan 70% in Preclinical Study
A longevity biotech called Immorta Bio published peer-reviewed findings showing that combining two aging-focused therapies extended lifespan by over 70% in preclinical models. The first therapy, SenoVax, helps the immune system clear senescent cells — aged, dysfunctional cells that linger and cause inflammation. The second, StemCellRevivify, uses stem cell approaches to restore the body's regenerative capacity. The key discovery was that regenerative therapies worked far better after senescent cells were removed first, suggesting the damaged cellular environment was blocking repair. Researchers also saw improvements in liver function and tissue recovery markers. The study is early-stage and not yet tested in humans, but it reinforces a growing view in longevity science that targeting multiple aging pathways simultaneously outperforms single-target strategies.
